Novel Telomerase-Targeting Immuno-oncology Platform: MAIA's lead drug, THIO, is designed to target telomerase, a unique mechanism of action intended to activate an anti-tumor immune response and sensitize cancer cells to existing immunotherapies, differentiating it from many current approaches.

Potential for Synergistic Combination Therapy: THIO is being developed to work in combination with checkpoint inhibitors (like PD-1/PD-L1 inhibitors), aiming to overcome resistance and improve response rates in patients who currently do not benefit sufficiently from these standard-of-care treatments.

Addressing Significant Unmet Medical Needs: The primary focus for THIO is on advanced non-small cell lung cancer (NSCLC) patients who are refractory or relapsed after prior checkpoint inhibitor therapy, representing a large patient population with limited treatment options.